Abstract
Objectives
The role of post-mastectomy radiotherapy (PMRT) in the management of node-negative T1-T2 tumors remains unclear. Clinical decision-making is more complex when suboptimal numbers of nodes are examined. The minimum number of negative nodes required in omitting PMRT in these patients is unknown.
Methods
This is a retrospective study of patients with T1-T2, node-negative tumors who had undergone modified radical mastectomy (MRM). Analyzed were the potential prognostic factors and the variables of taking chemotherapy, hormone therapy, PMRT, as well as the number of examined nodes in different cutoffs, from 0 to 9 nodes.
Results
Five hundred and three eligible patients were studied. The median follow-up was 60 months. The only prognostic factor was the variable of ≤3 vs. >3 nodes (P = 0.01). Other variables did not have a significant effect on the outcome. Analysis showed that without PMRT, the 5 and 10-year overall survival (OS) of 44 patients with ≤3 examined nodes were 76 and 63 %, respectively, and the 5- and 10-year OS rates of 155 patients with >3 examined nodes were 89 and <89 %, respectively (P = 0.02). In the group with PMRT, the 5- and 10-year OS rates of 102 patients with ≤3 examined nodes were 82 and 77 %, respectively, and the 5- and 10-year OS rates of 202 patients with >3 examined nodes were 92 and 88 %, respectively (P = 0.056).
Conclusion
According to the results of the current study on node-negative T1-T2 breast cancer patients, PMRT can overcome the inferior outcome of a suboptimal dissection and improve OS and is therefore recommended as a cutoff point if less than 4 nodes have been examined.
Similar content being viewed by others
References
Ragaz J, Olivotto IA, Spinelli JJ, et al. (2005) Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst 97:116–126
Overgaard M, Hansen PS, Overgaard J, et al. (1997) Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 337:949–955
Overgaard M, Jensen MB, Overgaard J, et al. (1999) Postoperative radiotherapy in high-risk postmenopausal breast-cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomized trial. Lancet 353:1641–1648
Truong PT, Olivotto IA, Whelan TJ, et al (2004) Principles and practice of oncology. Chapter 57, 1148–1150. Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170(8):1263–1273
Truong PT, Olivotto IA, Whelan TJ, et al. (2004) Clinical practice guidelines for the care and treatment of breast cancer: 16. Locoregional post-mastectomy radiotherapy. CMAJ 170(8):1263–1273
Recht A, Edge SB, Solin LJ, et al. (2001) Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 19:1539–1569
Strom EA, Woodward WA, Katz A, et al. (2005) Clinical investigation: regional nodal failure patterns in breast cancer patients treated with mastectomy without radiotherapy. Int J Radiat Oncol Biol Phys 63:1508–1513
Pierce LJ (2005) The use of radiotherapy after mastectomy: a review of the literature. J Clin Oncol 23:1706–1717
Fisher B, Wolmark N, Bauer M, et al. (1981) The accuracy of clinical nodal staging and of limited axillary dissection as a determinant of histologic nodal status in carcinoma of the breast. Surg Gynecol Obstet 152:765–772
Krag DN, Single RM (2003) Breast cancer survival according to number of nodes removed. Ann Surg Oncol 10:1152–1159
Wu SG, Chen Y, Sun JY, et al. (2013) Using the lymph nodal ratio to predict the risk of locoregional recurrence in lymph node-positive breast cancer patients treated with mastectomy without radiation therapy. Radiat Oncol 8:119
Edge SB, Byrd DR, Compton CC (2010) Chicago. Illinois AJCC cancer staging manual, 7th edn. Springer, New York
Kaplan E, Meier D (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457–481
Tausch C, Taucher S, Dubsky P, et al. (2012) Prognostic value of number of removed lymph nodes, and lymph node ratio in 7502 breast cancer patients enrolled onto trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG). Ann Surg Oncol 19(6):1808–1817
Schaapveld M, De Vries EG, van der Graaf WT, et al. (2006) The prognostic effect of the number of histologically examined axillary lymph nodes in breast cancer: stage migration or age association? Ann Surg Oncol 13(4):465–474
Dong G, Wang D, Liang X, et al. (2014) Factors related to survival rates for breast cancer patients. Int J Clin Exp Med 7(10):3719–3724
Wiznia LE, Lannin DR, Evans SB, et al. (2014) The number of lymph nodes dissected in breast cancer patients influences the accuracy of prognosis. Ann Surg Oncol 21(2):389–394
Fisher B (1981) A commentary on the role of the surgeon in primary breast cancer. Breast Cancer Res Treat 1:17–26
Martin FT, O'Fearraigh C, Hanley C, et al. (2013) The prognostic significance of nodal ratio on breast cancer recurrence and its potential for incorporation in a new prognostic index. Breast J 19(4):388–393
Axelsson CK, Mouridsen HT, Zedeler K, on behalf of the Danish Breast Cancer Cooperative Group (DBCG) (1992) Axillary dissection of level I and II lymph nodes is important in breast cancer classification. Eur J Cancer 128A:1415–1418
Somner JEA, Dixon JMJ, Thomas JSJ (2004) Node retrieval in axillary lymph node dissections: recommendations for minimum numbers to be confident about node negative status. J Clin Pathol 57:845–848
Vujovica O, Yua E, Cherianb A, et al. (2009) The number of axillary nodes removed as a predictor of regional recurrence in node negative breast cancer. Radiother Oncol 91(1):38–41
Tai P, Yu E, Sadikov E, et al. (2009) A long-term study of radiation therapy in T1-2 node-negative breast cancer patients in relation to the number of axillary nodes examined. Int J Radiat Oncol Biol Phys 74(2):453–457
Acknowledgments
The authors would like to thank all the colleagues at the Omid and Imam Reza oncology centers for their very kindly cooperation.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Funding
The work was supported by the Cancer Research Center, Faculty of Medicine, Mashhad University of Medical Sciences.
Conflict of interest
Author Roham Salek declares that he has no conflict of interest. Author Sareh Hosseini declares that she has no conflict of interest.
Ethical approval
This article does not contain any studies with human or animal subjects performed by any of the authors.
Informed consent
For this type of study, formal consent is not required.
Rights and permissions
About this article
Cite this article
Hosseini, S., Salek, R. Improving overall survival with post-mastectomy radiotherapy in a group of early-stage breast cancer: the number of negative lymph nodes sufficient to eliminate post-mastectomy radiotherapy. J Radiat Oncol 5, 395–399 (2016). https://doi.org/10.1007/s13566-016-0266-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13566-016-0266-3